Hodgkins disease

The development of extended-field radiotherapy, of chemothe and then of the combination of the two therapeutic modalities, led to cure rates of almost 80% in patients with Hodgkins dis (HD). The aim of management in patients presenting with must no longer be cure alone, but cure without sequelae and the best possible quality of life. Further efforts are necessar reduce the long-term toxicity of treatment and to improve prognosis of recurrent disease and that resistant to stan treatment. Numerous questions remain unanswered regardin heterogeneous histology and phenotypes of the disease the diversity of the clinical presentations. This document does not apply to patients who develop HD consequence of HIV disease. Similarly, the managemen patients with nodular lymphocyte-predominant HD (paragra loma of Poppema), which is considered to be a different e than HD, is not considered. The SOR document on the management of HD in adults published in full in 1998. An update is planned for the year 20 It will deal in particular with: